Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Clinica Universidad de Navarra, Universidad de Navarra
With
Spanish Clinical Research Network - SCReN
National Institutes of Health (NIH)
Chemotherapy schedule:
* dose dense epirubucin 100 mgr/m2 plus ciclofosfamide 600 mgr/m2 every two weeks for four cycles with with GM-CSF support on day +1 (pegylated filgastrim) or on days +5 to +9 (filgastrim) subcutaneously
* docetaxel 80-100 mgr/m2 every three weeks for four cycles. Addition of GM-CSF if docetaxel doses are \> 85 mgr/m2
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
HER2 negative and stage II and III Breast cancer patients who benefit with neoadjuvant chemotherapy
age 18-75
to get enough tumoral sample to elaborate the vaccine
You may not be if
pregnancy
severe diseases
hepatitis or HIV
need to be on immunosuppressant drugs
Clareo Health | Trial With Autologous Dendritic Cell Vaccination in Patients With Stage II-III HER2 Negative Breast Cancer
